Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS • Currently down 3.82 (-1.20%) in today's trading session

Track congressional stock trades in Alnylam Pharmaceuticals, Inc. (ALNY). Analyze trading activity from Nancy Pelosi and other members of Congress with real-time financial disclosure data, interactive price charts, and detailed transaction records.

Alnylam Pharmaceuticals, Inc. is currently trading at $313.41, positioned at 37% of its 52-week range ($205.87 – $495.55). View which politicians have recently bought or sold ALNY and how their trades align with market movements.

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio in real-time with just one click on eToro.

Free asset at sign up • Eligible regions only

Copy Portfolio Claim Free Asset

Live portfolio tracking

Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price

$313.41

24h Change

-3.82 (-1.20%)

52 Week Range

$205.87—$495.55

View on NASDAQ

Alnylam Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ALNY

Select to highlight on chart

Politician

2 transactions

Include Non-Compliant

Compliance: 100%


	Josh Gottheimer	11 Dec 2023	07 Jan 2024	Sale	Stock	$1,001 - $15,000	N/A (Sale Transaction)
	Josh Gottheimer	28 Sept 2022	16 Oct 2022	Purchase	Stock	$1,001 - $15,000	N/A (Price Data Unavailable)

Select transactions to view their annotations on the chart

Earnings

Next Report

Q1 2026

30 Apr

EPS Est.

$1.59

Rev. Est.

$1.1B

Days Until

Recent Quarters

Q4 202512 Feb

EPS$1.25

Beat 7.8%

Q3 202530 Oct

EPS$2.90

Beat 416.9%

Q2 202531 Jul

EPS$0.32

Beat 158.8%

Q1 20251 May

EPS$-0.01

Beat 98.9%

Q4 202413 Feb

EPS$0.06

Beat 109.7%

Q3 202431 Oct

EPS$-0.50

Beat 45.5%

Q2 20241 Aug

EPS$0.56

Beat 152.3%

Q1 20242 May

EPS$-0.16

Beat 85.7%

Q4 202315 Feb

EPS$-1.10

Beat 8.3%

Q3 20232 Nov

EPS$1.15

Beat 185.8%

Q2 20233 Aug

EPS$-2.21

Miss 28.5%

Q1 20234 May

EPS$-1.40

Beat 28.9%

Q4 202223 Feb

EPS$-1.68

Beat 21.1%

Q3 202227 Oct

EPS$-3.32

Miss 78.5%

Q2 202228 Jul

EPS$-2.29

Miss 41.4%

Q1 202228 Apr

EPS$-2.00

Miss 3.6%

Q4 202110 Feb

EPS$-2.16

Miss 46.9%

Q3 202128 Oct

EPS$-1.72

Miss 13.9%

Q2 20213 Aug

EPS$-1.61

Miss 2.5%

Q1 202129 Apr

EPS$-1.71

Beat 2.3%

Q4 202011 Feb

EPS$-2.09

Miss 8.3%

Q3 20205 Nov

EPS$-2.18

Miss 24.6%

Q2 20206 Aug

EPS$-1.56

Beat 12.8%

Q1 20206 May

EPS$-1.62

Beat 14.3%

Q4 20196 Feb

EPS$-2.47

Miss 9.8%

Q3 201931 Oct

EPS$-1.92

Beat 11.5%

Q2 20196 Aug

EPS$-1.83

Miss 1.1%

Q1 20191 May

EPS$-1.42

Beat 22.8%

Q4 20187 Feb

EPS$-1.82

Beat 7.6%

Q3 20187 Nov

EPS$-1.56

Beat 9.8%

Q2 20182 Aug

EPS$-1.61

Miss 4.5%

Q1 20183 May

EPS$-1.22

Miss 3.4%

Q4 20178 Feb

EPS$-1.48

Miss 7.3%

Q3 20177 Nov

EPS$-1.06

Beat 13.8%

Q2 20179 Aug

EPS$-1.07

Beat 9.3%

Q1 20175 May

EPS$-1.25

Miss 2.5%

Q4 20168 Feb

EPS$-1.32

Beat 2.2%

Q3 20162 Nov

EPS$-1.21

Miss 1.7%

Q2 20164 Aug

EPS$-1.05

Beat 16.7%

Q1 20162 May

EPS$-1.21

Miss 12.0%

Q4 201511 Feb

EPS$-1.07

Miss 5.9%

Q3 20159 Nov

EPS$-0.91

Beat 3.2%

Q2 20156 Aug

EPS$-0.85

Miss 14.9%

Q1 20157 May

EPS$-0.62

Beat 4.6%

Q4 201412 Feb

EPS$-0.11

Beat 80.7%

Q3 20145 Nov

EPS$-0.50

Beat 23.1%

Q2 20147 Aug

EPS$-0.63

Miss 16.7%

Q1 20148 May

EPS$-0.39

Beat 67.0%

Q4 201313 Feb

EPS$-0.42

Beat 12.5%

Q3 20136 Nov

EPS$-0.34

Beat 10.5%

Q2 20138 Aug

EPS$-0.24

Beat 29.4%

Q1 20136 May

EPS$-0.10

Beat 67.7%

Q4 20127 Feb

EPS$-0.54

Beat 68.2%

Q3 20125 Nov

EPS$-0.31

Beat 0.0%

Q2 20126 Aug

EPS$-0.25

Miss 31.6%

Q1 20123 May

EPS$-0.25

Beat 30.6%

Q4 20119 Feb

EPS$-0.33

Miss 3.1%

Q3 20111 Nov

EPS$-0.31

Beat 11.4%

Q2 20111 Aug

EPS$-0.33

Beat 8.3%

Q1 20112 May

EPS$-0.38

Miss 26.7%

Q4 201017 Feb

EPS$-0.16

Beat 54.3%

Q3 20103 Nov

EPS$-0.23

Beat 42.5%

Q2 20104 Aug

EPS$-0.35

Miss 16.7%

Q1 20105 May

EPS$-0.29

Beat 3.3%

Q4 200925 Feb

EPS$-0.19

Beat 36.7%

Q3 20094 Nov

EPS$-0.22

Beat 8.3%

Q2 20096 Aug

EPS$-0.55

Miss 12.2%

Q1 20097 May

EPS$-0.19

Beat 17.4%

Q4 200824 Feb

EPS$-0.23

Miss 53.3%

Q3 20085 Nov

EPS$-0.07

Beat 58.8%

Q2 20086 Aug

EPS$-0.31

Miss 106.7%

Q1 20088 May

EPS$-0.03

Beat 78.6%

Q4 20077 Feb

EPS$0.04

Beat 118.2%

Q3 20071 Nov

EPS$-1.35

Miss 35.0%

Q2 20079 Aug

EPS$-0.34

Miss 41.7%

Q1 20079 May

EPS$-0.58

Miss 107.1%

Q4 20067 Feb

EPS$-0.26

Beat 13.3%

Q3 20062 Nov

EPS$-0.23

Beat 28.1%

Q2 200626 Jul

EPS$-0.31

Miss 10.7%

Q1 20069 May

EPS$-0.30

Beat 23.1%

Q4 200515 Feb

EPS$-0.56

Miss 14.3%

Q3 20059 Nov

EPS$-0.51

Miss 50.0%

Q2 20053 Aug

EPS$-0.54

Miss 50.0%

Q1 200511 May

EPS$-0.32

Beat 0.0%

Q4 200415 Feb

EPS$-0.29

Miss 38.1%

Q3 200410 Nov

EPS$-0.33

Beat 8.3%

Q2 200412 Aug

EPS$-0.99

Q2 20044 Aug

EPS$-1.10

Miss 89.7%

Q3 200331 Dec

EPS$-3.78

Q2 200330 Sept

EPS$-7.41

Q1 200330 Jun

EPS$-6.02

Q4 200231 Mar

EPS$-4.62

1 politician traded within 30 days

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

No similar stocks found

No congressional trading patterns available for recommendations

Alnylam Pharmaceuticals, Inc. (ALNY)

Want to automatically copy Pelosi trades?

Alnylam Pharmaceuticals, Inc. Price History and Technical Analysis

Congressional Trading Activity for ALNY

Stock Overview

Market Data

Fundamentals

Company Information

Earnings

Next Report

Recent Quarters

Similar Stocks

Alnylam Pharmaceuticals, Inc. (ALNY)

Want to automatically copy Pelosi trades?

Alnylam Pharmaceuticals, Inc. Price History and Technical Analysis

Congressional Trading Activity for ALNY

Stock Overview

Market Data

Fundamentals

Company Information

Earnings

Next Report

Recent Quarters

Similar Stocks

Track ALNY in Congress